Press Releases

BOSTON --(BUSINESS WIRE)--Oct. 13, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

 - Initiates first-in-human trial of next-wave AAT corrector, VX-634 - - Phase 2 study evaluating the impact of longer-term treatment with VX-864 to be initiated in the coming weeks - - Additional AAT correctors to enter the clinic starting in 2023 - BOSTON --(BUSINESS WIRE)--Oct.

- Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - - EMA and MHRA submissions are on track for Q4 2022 - - Exa-cel granted Fast Track, Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug

BOSTON --(BUSINESS WIRE)--Sep. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022 . Mr. Biller will report directly to Vertex’s Chief Executive Officer and President, Reshma

-With this approval, approximately 300 children with two copies of the F508del mutation will have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Sep. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.

BOSTON --(BUSINESS WIRE)--Aug. 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Wells Fargo Healthcare Conference on Friday, September 9, 2022 at 11:00 a.m. ET . A live webcast of management’s remarks will be

— Product revenues of $2.20 billion , a 22% increase compared to Q2 2021 — — Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion — — Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta

- VX-548 advances into pivotal development for people with acute pain ; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - BOSTON --(BUSINESS WIRE)--Jul.

Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc.

BOSTON --(BUSINESS WIRE)--Jul. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

- ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets - - ViaCyte to be acquired for $320 million in cash- BOSTON --(BUSINESS WIRE)--Jul.

BOSTON --(BUSINESS WIRE)--Jul. 5, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated

–   Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure – – Safety profile generally consistent with myeloablative conditioning and

- TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show   improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fibrosis (CF) - - Study in people with CF

BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT .

- Vertex granted nine Breakthrough Therapy Designations and three PRIME designations across its pipeline programs to date – BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin

–   Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0 units per day of exogenous insulin at baseline to 99.9% and insulin independence at Day 270 – –   Patient 2 showed blood glucose time-in-range change from 35.9% on 25.9 units per day of exogenous insulin at baseline to 51.9%

 - Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation – BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics

BOSTON --(BUSINESS WIRE)--May 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated

BOSTON --(BUSINESS WIRE)--May 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay   has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the